1. Scrip
  2. >>New Products

GSK's Jemperli First-Line Endometrial Cancer Approval Fillip Ahead Of Keytruda Advance

With Restricted Label

 
• By Ayisha Sharma

The major’s PD-L1 inhibitor is the first to win US approval for the treatment of first-line endometrial cancer in combination with chemotherapy, but an unsurprisingly narrow label means rival Merck & Co.’s Keytruda could still make a splash in this indication.  

pink paper cut out of uterus
There Are 60,000 New Cases Of Endometrial Cancer Each Year In the US • Source: Shutterstock
Key Takeaways:

  • The label is limited to in mismatch repair deficient or microsatellite instability-high disease.

  • Rival Keytruda has shown efficacy in the broader proficient mismatch repair population.

  • GSK could still seek a broader label, but Keytruda’s reputation is likely to sway physicians.

GSK plc’s Jemperli has received a US Food and Drug Administration green light for use with chemotherapy in mismatch repair deficient (dMMR) or microsatellite instability-high (MSI-H) first-line endometrial cancer...

Jemperli (dostarlimab) first won US approval in 2021 for second-line treatment of patients with dMMR recurrent or advanced endometrial cancer, with a subsequent label expansion to all other dMMR recurrent...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from New Products

Boehringer’s CMO On How AI, Integrated Evidence Generation Underpin Its Ambitious Launch Plans

 
• By Alexandra Shimmings

The German company has big plans for the next five years or so. Scrip speaks to its chief medical officer Lykke Hinsch Gylvin about how it is using AI and other innovative approaches to make good on its ambitions.

Pipeline Watch: Eight Approvals And Nineteen Phase III Readouts

Pipeline Watch is a weekly snapshot of selected late-stage clinical trial events and approvals announced by pharmaceutical and biotech companies at medical and industry conferences, in financial and company presentations, and in company releases and statements.

In Brief: US FDA Delay Sends Biohaven Shares Down

 
• By Andrew McConaghie

The US regulator’s decision has taken Biohaven and investors by surprise, with the reason for a ‘major amendment’ status not clear.

Strong Showing For Bayer’s Pharma Business In Uncertain Times

 
• By Kevin Grogan

As CEO Anderson backs high prices for innovative drugs in Europe

More from Scrip

Merus Bispecific Impresses In Head And Neck Cancer

 
• By Andrew McConaghie

Updated Phase II results from petosemtamab have impressed ahead of ASCO, outshining Keytruda monotherapy and its bispecific rival from Bicara.

Zydus To Continue Mirabegron Sales, Looks To World-First Dual Shigella-Typhoid Vaccine

 
• By Vibha Ravi

Zydus expects strong mirabegron sales in FY26 amid US litigation even as it builds a growth pillar in vaccines with a world-first, Gates Foundation-aided dual shigella-typhoid vaccine under development and others on the WHO prequalified list

Challenging Environment For Biopharma Is A Tailwind For Royalty Pharma

 
• By Jessica Merrill

The royalty revenue stream acquirer has around 40 products in its portfolio and expects to generate roughly $3bn this year. Head of R&D and investments Marshall Urist talked about the investment strategy at the RBC Healthcare Conference.